Tenax Therapeutics is hitting pause on signing up new patients for its LEVEL-2 clinical trial.

Oct 8, 2026, 4:19 PM ETTrialRead the original at SEC EDGAR

Neutral

Tenax is changing LEVEL-2's enrollment rules to focus on patients its earlier study suggests may benefit more. The benefit is not yet shown in LEVEL-2, and enrollment is paused during the change, so this update does not change the company's outlook.

TENX · Tenax Therapeutics, Inc.

AI read · Neutral

The AI's read

A narrower focus could help the study detect improved exercise tolerance. But LEVEL-2 has not shown that benefit, and enrollment is paused as sites adopt the new rules. Tenax has also only requested an FDA meeting. These possible gains and delays leave the company's outlook unchanged.

Get alerts for TENX

Follow Tenax Therapeutics, Inc. (TENX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TENX

Free on the App Store and Google Play, or on the web.